Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947904 | 0.66 | PDGFRB (0.31) | — | |
| SCHEMBL14947900 | 0.65 | PTGS2 (0.30) | — | |
| SCHEMBL1512753 | 0.65 | USP8 (0.36) | KMT2A | |
| SCHEMBL2376041 | 0.62 | MAPK8 (0.56) | ROCK2AKT2AKT1POLBKMT2A | |
| SCHEMBL17641728 | 0.62 | MAPT (0.52) | TGFBR1KMT2A | |
| SCHEMBL7918824 | 0.62 | IDO1 (0.43) | CDK2CCNA1 | |
| SCHEMBL18296888 | 0.61 | ACVR1 (0.36) | CDK2CCNA1TGFBR1AKT2AKT1 | |
| SCHEMBL14947897 | 0.61 | MAPK14 (0.30) | — | |
| SCHEMBL20231933 | 0.60 | KCNJ1 (0.60) | — | |
| SCHEMBL23252642 | 0.60 | AHR (0.41) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | CES2, DNPEP, METAP2 | ROCK2 3174/4885CCNA2 2561/4885CDK2 1822/4885 |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | CES2, DNPEP, METAP2 | ROCK2 3174/4885CCNA2 2561/4885CDK2 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.